David J. Clark
Chief Tech/Sci/R&D Officer presso TREVI THERAPEUTICS, INC.
Profilo
David J.
Clark is currently a Member at The Royal College of Physicians, President at Pasteur Merieux MSD Ltd., and Chief Medical Officer at Trevi Therapeutics, Inc. He previously held positions as President & Chief Executive Officer at Neose Technologies, Inc., MedImmune Vaccines, Inc., and Oncology.com, Inc. He also served as Chairman at Mersana Therapeutics, Inc. and TOLMAR Therapeutics, Inc., and as Executive Chairman at LigoCyte Pharmaceuticals, Inc. Additionally, he has held director positions at OraVax, Inc., FluGen, Inc., and NovaDigm Therapeutics, Inc. He worked as a Principal at Pfizer Inc., GSK Plc, and SmithKline Beecham Ltd.
Furthermore, he served as Senior Vice President-Translational Medicine at VTVX Holdings I LLC from 2011 to 2013, Chief Medical Officer at Aldeyra Therapeutics, Inc. from 2016 to 2020, Chief Medical Officer at NormOxys, Inc. from 2009 to 2011, Chief Medical Officer at Wilson Therapeutics AB from 2013 to 2015, and Chief Medical Officer at Allena Pharmaceuticals, Inc. from 2020 to 2022.
Dr. Clark obtained a doctorate degree from The University of Edinburgh in 1987.
Posizioni attive di David J. Clark
| Società | Posizione | Inizio |
|---|---|---|
| TREVI THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 14/11/2022 |
| Pasteur Merieux MSD Ltd. | President | - |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Precedenti posizioni note di David J. Clark
| Società | Posizione | Fine |
|---|---|---|
| ALLENA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01/09/2022 |
| ALDEYRA THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 12/03/2020 |
| WILSON THERAPEUTICS AB | Chief Tech/Sci/R&D Officer | 01/01/2015 |
VTVX Holdings I LLC
 VTVX Holdings I LLC Miscellaneous Commercial ServicesCommercial Services VTVX Holdings I LLC discovers, develops and commercializes human therapeutics to fill unmet medical needs. Its products include a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a range of human diseases, including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, metabolic diseases, inflammatory diseases, female sexual dysfunction, primary open angle glaucoma and cancer. The company was founded in 1998 by Dr. Adnan M. M. Mjalli and is headquartered in High Point, NC. | Corporate Officer/Principal | 01/02/2013 |
NormOxys, Inc.
 NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Chief Tech/Sci/R&D Officer | 01/01/2011 |
Formazione di David J. Clark
| The University of Edinburgh | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 6 |
|---|---|
| PFIZER, INC. | Health Technology |
| ALDEYRA THERAPEUTICS, INC. | Health Technology |
| MERSANA THERAPEUTICS, INC. | Health Technology |
| GSK PLC | Health Technology |
| TREVI THERAPEUTICS, INC. | Health Technology |
| ALLENA PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 13 |
|---|---|
Neose Technologies, Inc.
 Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
OraVax, Inc.
 OraVax, Inc. BiotechnologyHealth Technology Part of Sanofi, OraVax, Inc. is a private company that has a slick name that taps into the words 'oral' and 'vaccine' in a subtle way. The company is based in Cambridge, MA. The company is a possible oral health brand, medical licensing service, app, or chemicals company. OraVax was acquired by Acambis Plc, part of Sanofi from September 22, 2008 on May 11, 1999 for $17.79 million. | Health Technology |
MedImmune Vaccines, Inc.
 MedImmune Vaccines, Inc. BiotechnologyHealth Technology MedImmune Vaccines, Inc. develops, manufactures and markets live vaccines. Its developed vaccine is inhaled FluMist. The company is located in Mountain View, CA | Health Technology |
VTVX Holdings I LLC
VTVX Holdings I LLC Miscellaneous Commercial ServicesCommercial Services VTVX Holdings I LLC discovers, develops and commercializes human therapeutics to fill unmet medical needs. Its products include a pipeline of small molecule clinical and pre-clinical drug candidates for the treatment of a range of human diseases, including central nervous system disorders, cardiovascular disorders, type I/II diabetes, obesity, metabolic diseases, inflammatory diseases, female sexual dysfunction, primary open angle glaucoma and cancer. The company was founded in 1998 by Dr. Adnan M. M. Mjalli and is headquartered in High Point, NC. | Commercial Services |
NormOxys, Inc.
NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Health Technology |
FluGen, Inc.
 FluGen, Inc. Pharmaceuticals: MajorHealth Technology Flugen, Inc. develops and produces influenza vaccines. Its products include a live attenuated vaccine candidate, a cell-line technology that provides vaccine production efficiency and capacity, and a novel, vaccine-loaded intradermal delivery technology. The company was founded by Yoshihiro Kawaoka, Gabriele Neumann and Paul Radspinner in 2007 and is headquartered in Madison, WI. | Health Technology |
TOLMAR Therapeutics, Inc.
 TOLMAR Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TOLMAR Therapeutics, Inc. provides healthcare services. The company's products include Eligard, a prostate cancer treatment, Aczone, a dermatology product for the treatment of acne, and Atrigel, a drug delivery system. Its drug delivery systems deliver medicines such as proteins and antibiotics. The company also makes Orajel and Cepacol mouth sore medicines. It is headquartered in Fort Collins, CO. | Health Technology |
| LigoCyte Pharmaceuticals, Inc. | Health Technology |
| Pasteur Merieux MSD Ltd. | |
NovaDigm Therapeutics, Inc.
 NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | Health Technology |
SmithKline Beecham Ltd.
 SmithKline Beecham Ltd. Pharmaceuticals: MajorHealth Technology Smithkline Beecham Ltd. manufacture of basic pharmaceutical products. It also provides mineral water, bottled water, and soft drinks. The company was founded on January 24, 1989 and is headquartered in Brentford, the United Kingdom. | Health Technology |
Oncology.com, Inc.
 Oncology.com, Inc. Internet Software/ServicesTechnology Services Oncology.com, Inc. provides online cancer news and information. The company is based in New York, NY. The company was founded by David B. Agus. Oncology.com was acquired by Pharmacia Corp. on March 15, 2001. | Technology Services |
Wilson Therapeutics AB
 Wilson Therapeutics AB Pharmaceuticals: MajorHealth Technology Wilson Therapeutics AB engages in the development of novel therapies for patients with rare copper-mediated disorders. The company was founded on April 25, 2012 and is headquartered in Stockholm, Sweden. | Health Technology |
- Borsa valori
- Insiders
- David J. Clark
